STATUTORY RULES
1968 No.
REGULATIONS UNDER THE NATIONAL HEALTH ACT 1953-1968.*
I, THE GOVERNOR-GENERAL in and over the Commonwealth of Australia, acting with the advice of the Federal Executive Council, hereby make the following Regulations under the National Health Act 1953-1968.
Dated this twenty-ninth day of November, 1968.
CASEY
Governor-General.
By His Excellency's Command,
(SGD.) A, J. FORBES
Minister of State for Health.
Amendments of the National Health (Pharmaceutical Benefits) regulations†
Commencement.
1. These Regulations shall come into operation on the first day of December, 1968.
First Schedule.
2. The First Schedule to the National Health (Pharmaceutical Benefits) Regulations is amended by omitting item 57 and inserting in its stead the following item:—
" 57. Chloroquine Phosphate ".
Second Schedule.
3. The Second Schedule to the National Health (Pharmaceutical Benefits) Regulations is amended as set out in the First Schedule to these Regulations.
Third Schedule.
4. The Third Schedule to the National Health (Pharmaceutical Benefits) Regulations is amended as set out in the Second Schedule to these Regulations.
Fifth Schedule.
5. The Fifth Schedule to the National Health (Pharmaceutical Benefits) Regulations is repealed and the following Schedule inserted in its stead:—
* Notified in the Commonwealth Gazette on 1968.
† Statutory Rules I960, No. 17, as amended to date. For previous amendments of the National Health (Pharmaceutical Benefits) Regulations, see footnote to Statutory Rules 1968, No. 44, and see also Statutory Rules 1968, Nos. 44, 76 and 88.
24573/68—Price 30c 15/20.11.1968
FIFTH SCHEDULE
Regulation 14.
Pharmaceutical Benefits the Prescribing of Which is Subject to Conditions and Restrictions
First Column_Column | Third Column | |
Item No. | Pharmaceutical Benefit | Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act |
1 | Acetylcysteine............. | Fibrocystic disease |
2 | (1) Acetylsalicylic Acid Tablets, B.P | Any disease or condition in a pensioner |
| (2) Soluble Acetylsalicylic Acid Tablets B.P. |
|
| (3) Acetylsalicylic Acid with Paracetamol and Caffeine Tablets |
|
| (4) Acetylsalicylic Acid with Codeine Phosphate and Pentobarbitone Sodium |
|
3 | Acrylic Resin .............. | Ileostomy or colostomy conditions |
4 | Aldosterone ............... | With the written authority of the Director-General, treatment of an acute crisis in— |
|
| Addison's disease |
|
| Salt-losing congenital adrenal hypoplasia |
5 | Allopurinol ............... | Chronic gout not responding to other pharmaceutical benefits |
|
| Gout associated with renal failure |
6 | Aloxiprin ................ | Any disease or condition in a pensioner |
7 | Aluminium Hydroxide Gel with Kaolin | Ileostomy or colostomy conditions |
8 | Aluminium Acetylsalicylate Tablet | Any disease or condition in a pensioner |
9 | Aminocaproic Acid.......... | Any disease or condition in a patient receiving treatment in or at an approved hospital |
10 | (1) Amitriptyline Hydrochloride . | Any disease or condition in a pensioner |
| (2) Amitriptyline Tablets, B.P | Any disease or condition in a patient receiving treatment in or at an approved hospital |
|
| The treatment of a mental disorder in a person who has, after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that that person received treatment at the hospital and may require further treatment with Amitriptyline Hydrochloride or Amitriptyline Tablets, B.P. |
|
| With the written authority of the Director-General, the treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital |
11 | Amphetamine Sulphate Tablets, B.P. | Any disease or condition in a pensioner |
12 | Amphotericin B ............ | Systemic fungal infection |
13 | (1) Ampicillin Capsules, B.P.... | With the written authority of the Director-General— |
| (2) Ampicillin Injections, Tablets | Gram-negative infections in pregnant women |
| and Suspension | Infections in children, in which penicillin and sulphonamides are not effective |
|
| Infections where positive bacteriological evidence confirms that ampicillin is an appropriate therapeutic agent and the Director-General is satisfied that it is the most appropriate therapeutic agent in all the circumstances of the case |
|
| Acute infections threatening the life of a patient where clinical evidence shows that ampicillin is an appropriate therapeutic agent and the Director-General is satisfied that it is the most appropriate therapeutic agent in all the circumstances of the case |
|
| Chronic bronchitis complicated by emphysema where other therapeutic agents have failed |
Fifth Schedule—continued
First Column_Column | Third Column | |
Item No. | Pharmaceutical Benefit | Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be proscribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act |
14 | Aneurine Hydrochloride Tablets B.P. | Any disease or condition in a pensioner |
15 | Angiotensin Amide .......... | Any disease or condition in a patient receiving treatment in or at an approved hospital |
16 | Ascorbic Acid Tablets, B.P..... | Any disease or condition in a pensioner |
17 | (1) Azathioprine ............ | Any disease or condition in a patient receiving treatment in or at an approved hospital |
| (2) Beclamide |
|
18 | Benzoin Compound Tincture, B.P.C. | Ileostomy or colostomy conditions |
19 | Benzylpenicillin Injection, 5,000,000 units | Bacterial endocarditis or septicaemia |
20 | Benzylpenicillin Injection, 10,000,000 units | Bacterial endocarditis or septicaemia Gastrointestinal surgery |
21 | (1) Benzylpenicillin with Streptomycin Sulphate | Endocarditis due to Streptococcus faecalis or Streptococcus viridans |
| (2) Benzylpenicillin with Procaine Penicillin and Streptomycin Sulphate |
|
22 | Betamethasone Tablets ....... | With the written authority of the Director-General— |
|
| Acquired haemolytic anaemia |
|
| Acute disseminated encephalomyelitis |
|
| Acute exfoliative dermatitis |
|
| Acute exophthalmic ophthalmoplegia |
|
| Acute heart block complicating myocardial infarction |
|
| Acute phase of herpes zoster |
|
| Acute rheumatic carditis |
|
| Adrenogenital syndrome |
|
| Agranulocytosis |
|
| Behcet's syndrome |
|
| Benign intracranial hypertension |
|
| Cerebral oedema |
|
| Cerebral tumors |
|
| Cranial arteritis |
|
| Cushing's syndrome including hyperadrenocorticalism |
|
| Dermatomyositis |
|
| Encephalitis |
|
| Encephalomyelitis |
|
| Giant cell thyroiditis proven by biopsy |
|
| Guillain-Barre syndrome |
|
| Hamman-Rich syndrome—diffuse interstitial pulmonary fibrosis |
|
| Hansen's disease |
|
| Hepatitis, progressive or continuing, proven by biopsy or biochemistry |
|
| Hodgkin's disease |
|
| Hypoplastic anaemia |
|
| Idiopathic hypercalcaemia |
|
| Inflammatory conditions of the uveal tract and retina |
|
| Interstitial keratitis dueto syphilis or vernal conjunctivitis |
|
| Keratoplasty |
|
| Leucine sensitive hypoglycaemia |
|
| Leukaemia |
|
| Lymphosarcoma and follicular lymphoma |
|
| Malignancy treatment in conjunction with radiotherapy or chemotherapy |
|
| Meningitis |
|
| Metastatic breast cancer |
|
| Mycosis fungoides |
Fifth Schedule—continued
First Column_Column | Third Column | |
Item No. | Pharmaceutical Benefit | Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act |
22 | Betamethasone Tablets—continued | Nephrosis or nephrotic syndrome |
|
| Neuromyelitis optica |
|
| Nodular non-suppurative panniculitis (Christian-Weber disease) |
|
| Oedema of the spinal cord following trauma or infections |
|
| Optic neuritis following removal of tumors of the brain |
|
| Panhypopituitarism |
|
| Pemphigus |
|
| Periarteritis |
|
| Progressive transverse myelitis |
|
| Pseudohermaphroditism |
|
| Pulmonary eosinophilia |
|
| Purpura, Henoch's |
|
| Regional ileitis (Crohn's disease) |
|
| Reticulum cell sarcoma |
|
| Sarcoidosis |
|
| Scleroderma |
|
| Severe reactions of the skin and mucosa following X-ray therapy |
|
| Sneddon and Wilkinson's subcorneal pustular dermatosis |
|
| Splenic neutropenia |
|
| Status asthmaticus |
|
| Steroid therapy prior to operation for those patients under steroid therapy |
|
| Stevens-Johnson syndrome |
|
| Still's disease in children under the age of sixteen years |
|
| Systemic lupus erythematosus |
|
| Sympathetic ophthalmitis |
|
| Temporal arteritis |
|
| Thrombocytopenic purpura |
|
| Tropical and non-tropical sprue and forms of malabsorption associated with these diseases |
|
| Type II nephritis |
|
| Ulcerative colitis proven by sigmoidoscopy or radiological report. |
23 | Betamethasone Acetate and Betamethasone Alcohol Injection | Intra-articular use |
24 | Betamethasone Sodium Phosphate Injection, B.P. | Intra-articular use |
25 | Buclosamide and Salicylic Acid | For the treatment of diseases of the car |
26 | Buclosamide, Salicylic Acid and Hydrocortisone Acetate | For the treatment of diseases of the car |
27 | Busulphan Tablets, B.P........ | Treatment in neoplastic disease |
28 | (1) Calciferol Tablets, B.P...... | Any disease or condition in a pensioner |
| (2) Calciferol, B.P........... | With the written authority of the Director-General— |
|
| Hypoparathyroidism |
|
| Chronic hypoparathyroid tetany |
|
| Vitamin D-resistant rickets |
29 | Calcium Aminosalicylate...... | Tuberculosis |
30 | Carbamazepine............. | Epilepsy |
|
| Trigeminal neuralgia |
31 | (1) Carbenoxolone Sodium..... | Any disease or condition in a patient receiving treatment in or at an approved hospital |
| (2) Cephaloridine........... | |
32 | Charcoal Tablets............ | Ileostomy or colostomy conditions |
33 | Chlorambucil Tablets, B.P...... | Treatment in neoplastic disease |
34 | Chloramine Deodorant Tablets and Powder | Ileostomy or colostomy conditions |
Fifth Schedule—continued
First Column_Column | Third Column | |
Item No. | Pharmaceutical Benefit | Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act |
35 | Chloramphenicol Capsules, B.P. | Bacterial meningitis |
|
| Haemophilus influenzae infections |
|
| Intra-ocular infections |
|
| Rickettsial infections |
|
| Salmonella septicaemia |
|
| Typhoid and paratyphoid |
|
| Other serious infections sensitive only to Chloramphenicol Capsules, B.P. |
36 | (1) Chloramphenicol Injections..... | A disease or condition specified in this column in relation to Chloramphenicol Capsules, B.P. |
| (2) Chloramphenicol Tablets ....... |
|
| (3) Chloramphenicol Oral Suspension |
|
37 | Chlorotrianisene Tablets.......... | Carcinoma of the prostate |
38 | (1) Chlorpromazine Hydrochloride, B.P. | Any disease or condition in a pensioner |
|
| Any disease or condition in a patient receiving treatment in or at tin approved hospital |
| (2) Chlorpromazine Injection, B.P. |
|
| (3) Chlorpromazine Tablets, B.P. | The treatment of a mental disorder in a person who hits, after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that that person received treatment at the hospital and may require further treatment with Chlorpromazine Hydrochloride, B.P., Chlorpromazine Hydrochloride Injection, B.P., or Chlorpromazine Tablets, B.P. |
|
| With the written authority of the Director-General— |
|
| Late-stage malignancy |
|
| Radiation sickness |
|
| Huntington's chorea |
|
| With the written authority of the Director-General, the treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital |
39 | Chlortetracycline Capsules, B.P.. | Brucellosis |
|
| Herpes zoster opthalmicus |
|
| Intestinal amoebiasis |
|
| Leptospirosis |
|
| Lymphogranuloma venereum |
|
| Psittacosis |
|
| Rickettsial infections |
|
| Any bacterial infections or actinomycosis or trachoma where these cannot be treated safely and effectively by sulphonamides or penicillins |
|
| Pre-operative and post-operative therapy where there are reasonable grounds for believing that infection may occur |
40 | Chlortetracycline Hydrochloride Granules | A disease or condition specified in this column in relation to Chlortetracycline Capsules, B.P. |
41 | (1) Cloxacillin Sodium, B.P........ | Any disease or condition in a patient receiving treatment in or at an approved hospital |
| (2) Cloxacillin Capsules, B.P |
|
42 | (1) Codiene Phosphate with Acetylsalicylic Acid Soluble Tablets | Any disease or condition in a pensioner |
| (2) Codiene Phosphate with Acetylsalicylic Acid Tablets |
|
| (3) Codeine Phosphate with Acetylsalicylic Acid and Paracetamol Soluble Tablets |
|
| (4) Codeine Phosphate with Acetylsalicylic Acid, Paracetamol and Caffeine Tablets |
|
43 | Cod Liver Oil Emulsion .......... | Any disease or condition in a child under the age of twelve years or in a pensioner |
Fifth Schedule—continued
First Column_Column | Third Column | |
Item No. | Pharmaceutical Benefit | Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act |
44 | Colistin Sulphomethate Injection, B.P. | Pyocyaneus infection and Gram-negative infections where no other drug is effective |
45 | (1) Corticotrophin Injection, B.P. | With the written authority of the Director-General— |
| (2) Corticotrophin Gelatin Injection, B.P. | The prevention of side effects of corticosteroid therapy |
| (3) Corticotrophin Zinc Hydroxide Injection, B.P. | Acquired haemolytic anaemia |
|
| Acute disseminated encephalomyelitis |
|
| Acute exacerbations of multiple sclerosis |
|
| Acute exfoliative dermatitis |
|
| Acute phase of Bell's Palsy |
|
| Acute rheumatic carditis |
|
| Addison's disease or other forms of adrenocortical hypoplasia |
|
| Adrenogenital syndrome |
|
| Agranulocytosis |
|
| Behcet's syndrome |
|
| Cranial arteritis |
|
| Cushing's syndrome including hyperadrenocorticalism |
|
| Dermatomyositis |
|
| Encephalomyelitis |
|
| Giant cell thyroiditis proven by biopsy |
|
| Guillain-Barré syndrome |
|
| Hamman-Rich syndrome—diffuse interstitial pulmonary fibrosis |
|
| Hansen's disease |
|
| Hepatitis, progressive or continuing, proven by biopsy or biochemistry |
|
| Hodgkin's disease |
|
| Hypoplastic anaemia |
|
| Hypsarrhythmia |
|
| Idiopathic hypercalcaemia |
|
| Inflammatory conditions of the uveal tract and retina |
|
| Keratoplasty |
|
| Leucine sensitive hypoglycaemia |
|
| Leukaemia |
|
| Lymphosarcoma and follicular lymphoma |
|
| Metastatic breast cancer |
|
| Mycosis fungoides |
|
| Nephrosis or nephrotic syndrome |
|
| Neuromyelitis optica |
|
| Optic neuritis following removal of tumors of the brain |
|
| Panhypopituitarism |
|
| Pemphigus |
|
| Periarteritis |
|
| Progressive transverse myelitis |
|
| Pseudohermaphroditism |
|
| Pulmonary cosinophilia |
|
| Purpura, Henoch's |
|
| Regional ileitis (Crohn's disease) |
|
| Reticulum cell sarcoma |
|
| Salaam convulsions |
|
| Sarcoidosis |
|
| Scleroderma |
|
| Severe reactions of the skin and mucosa following X-ray therapy |
|
| Splenic neutropenia |
|
| Status asthmaticus |
|
| Steroid therapy prior to operation for those patients under steroid therapy |
|
| Stevens-Johnson syndrome |
Fifth Schedule—continued
First Column_Column | Third Column | |
Item No. | Pharmaceutical Benefit | Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act |
45 | (1) Corticotrophin Injection, B.P. | Still's disease in children under the age of sixteen years |
| (2) Corticotrophin Gelatin Injection, B.P. |
|
|
| Systemic lupus erythematosus |
| (3) Corticotrophin Zinc Hydroxide | Sympathetic ophthalmitis |
| Injection, B.P.—continued | Temporal arteritis |
|
| Thrombocytopenic purpura |
|
| Tropical and non-tropical sprue and forms of malabsorption associated with these diseases |
|
| Type II nephritis |
|
| Ulcerative colitis proven by sigmoidoscopy or radiological report |
46 | Cortisone Injection, B.P.......... | With the written authority of the Director-General— |
|
| Acute exophthalmic ophthalmoplegia |
|
| Acute heart block complicating myocardial infarction |
|
| Anaemia, acquired haemolytic |
|
| Addison's disease |
|
| Adrenocortical hypoplasia |
|
| Adrenalectomy, total |
|
| Adrenogenital syndrome |
|
| Agranulocytosis |
|
| Behcet's syndrome |
|
| Benign intracranial hypertension |
|
| Cerebral tumours and cerebral oedema |
|
| Cranial arteritis |
|
| Cushing's syndrome, including hyperadrenocorticalism |
|
| Dermatitis, acute exfoliative |
|
| Dermatomyositis |
|
| Encephalitis |
|
| Encephalomyelitis |
|
| Encephalomyelitis, acute disseminated |
|
| Giant cell thyroiditis proven by biopsy |
|
| Guillain-Barré syndrome |
|
| Hamman-Rich syndrome—diffuse interstitial pulmonary fibrosis |
|
| Hansen's disease |
|
| Hepatitis, progressive or continuing, proven by biopsy or biochemistry |
|
| Hodgkin's disease |
|
| Hypoplastic anaemia |
|
| Idiopathic hypercalcaemia |
|
| Inflammatory conditions of the uveal tract and retina |
|
| Interstitial keratitis due to syphilis or vernal conjunctivitis |
|
| Keratoplasty |
|
| Leucine sensitive hypoglycaemia |
|
| Leukaemia |
|
| Lymphosarcoma and follicular lymphoma |
|
| Meningitis |
|
| Metastatic breast cancer |
|
| Mycosis fungoides |
|
| Nephrosis or nephrotic syndrome |
|
| Neuromyelitis optica |
|
| Oedema of the spinal cord following trauma or infection |
|
| Optic neuritis following removal of tumor of the brain |
|
| Panhypopituitarism |
|
| Pemphigus |
|
| Periarteritis |
|
| Progressive transverse myelitis |
Fifth Schedule—continued
First Column_Column | Third Column | |
Item No. | Pharmaceutical Benefit | Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act |
46 | Cortisone Injection, B.P.—continued | Pseudohermaphroditism |
|
| Pulmonary cosinophilia |
|
| Purpura, Henoch's |
|
| Purpura, thrombocytopenic |
|
| Regional ileitis (Crohn's disease) |
|
| Reticulum cell sarcoma |
|
| Rheumatic carditis, acute |
|
| Sarcoidosis |
|
| Scleroderma |
|
| Severe reactions of the skin and mucosa following X-ray therapy |
|
| Splenic neutropenia |
|
| Status asthmaticus |
|
| Steroid therapy prior to operation in patients under steroid therapy |
|
| Stevens-Johnson syndrome |
|
| Still's disease in a child under the age of sixteen years |
|
| Sneddon and Wilkinson's sub-corneal pustular dermatosis |
|
| Sympathetic ophthalmitis |
|
| Systemic lupus erythematosus |
|
| Temporal arteritis |
|
| Treatment of malignancy in conjunction with radiotherapy or chemotherapy |
|
| Tropical and non-tropical sprue and all forms of malabsorption associated with those diseases |
|
| Type II Nephritis |
|
| Ulcerative colitis proven by sigmoidoscopy or radiological report |
47 | Cortisone Tablets, B.P........... | With the written authority of the Director-General, a disease or condition specified in this column in relation to Cortisone Injection, B.P. |
48 | Cyanocobalamin Injection, B.P..... | Established megalocytic anaemia |
|
| Neuroblastoma |
|
| Sub-acute combined degeneration of the cord |
|
| Treatment in post-gastrectomy |
49 | Cymogran | With the written authority of the Director-General, phenylketonuria |
50 | (1) Cycloserine Tablets, B.P....... | Any disease or condition in a patient receiving treatment in or at an approved hospital |
| (2) Cycloserine Capsules, B.P. |
|
51 | (1) Demethylchlortetracycline Capsules, B.P. | A disease or condition specified in this column in relation to Chlortetracycline Capsules, B.P., except herpes zoster ophthalmicus |
| (2) Demethylchlortetracycline |
|
| Hydrochloride Oral Paediatric |
|
| Drops and Oral Suspension |
|
52 | Demethylchlortetracycline Hydrochloride with Nystatin | Any disease or condition specified in this column in relation to Oxytetracycline Hydrochloride with a buffering agent and Nystatin |
53 | Deodorant Detergent Solution (Terric with Spearmint Oil and Cetrimide) | Ileostomy or colostomy conditions |
54 | (1) Deoxycortone Aqueous Injections | Addison's disease |
|
| Adrenalectomy, total |
| (2) Deoxycortone Acetate Injection, B.P. |
|
| (3) Deoxycortone Trimethylacetate Injection, B.P. |
|
| (4) Deoxycortone Acetate Implants, B.P. |
|
| (5) Deoxycortone Acetate Tablets |
|
55 | Desferrioxamine ............... | Any disease or condition in a patient receiving treatment in or at an approved hospital |
Fifth Schedule—continued
First Column_Column | Third Column | |
Item No. | Pharmaceutical Benefit | Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act |
56 | Dexamethasone Tablets, B.P....... | With the written authority of the Director-General— |
|
| Acquired haeomolytic anaemia |
|
| Acute disseminated encephalomyelitis |
|
| Acute exfoliative dermatitis |
|
| Acute exophthalmic ophthalmoplegia |
|
| Acute heart block complicating myocardial infarction |
|
| Acute phase of herpes zoster |
|
| Acute rheumatic carditis |
|
| Adrenogenital syndrome |
|
| Agranulocytosis |
|
| Behcet's syndrome |
|
| Benign intracranial hypertension |
|
| Cerebral oedema |
|
| Cerebral tumors |
|
| Cranial arteritis |
|
| Cushing's syndrome including hyperadrenocorticalism |
|
| Dermatomyositis |
|
| Encephalitis |
|
| Encephalomyelitis |
|
| Giant cell thyroiditis proven by biopsy |
|
| Guillain-Barré syndrome |
|
| Hamman-Rich syndrome—diffuse interstitial pulmonary fibrosis |
|
| Hansen's disease |
|
| Hepatitis, progressive or continuing, proven by biopsy or biochemistry |
|
| Hodgkin's disease |
|
| Hypoplastic anaemia |
|
| Idiopathic hypercalcaemia |
|
| Inflammatory conditions of the uveal tract and retina |
|
| Interstitial keratitis due to syphilis or vernal conjunctivitis |
|
| Keratoplasty |
|
| Leucine sensitive hypoglycaemia |
|
| Leukaemia |
|
| Lymphosarcoma and follicular lymphoma |
|
| Malignancy treatment in conjunction with radiotherapy or chemotherapy |
|
| Meningitis |
|
| Metastatic breast cancer |
|
| Mycosis fungoides |
|
| Nephrosis or nephrotic syndrome |
|
| Neuromyelitis optica |
|
| Nodular nonsuppurative panniculitis (Christian-Weber disease) |
|
| Oedema of the spinal cord following trauma or infections |
|
| Optic neuritis following removal of tumors of the brain |
|
| Panhypopituitarism |
|
| Pemphigus |
|
| Periarteritis |
|
| Progressive transverse myelitis |
|
| Pseudohermaphroditism |
|
| Pulmonary eosinophilia |
|
| Purpura, Henoch's |
|
| Regional ileitis (Crohn's disease) |
|
| Reticulum cell sarcoma |
|
| Sarcoidosis |
|
| Scleroderma |
Fifth Schedule—continued
First Column | Second Column | Third Column |
Item No. | Pharmaceutical Benefit | Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act |
56 | Dexamethasone Tablets, B.P.—continued | Severe reactions of the skin and mucosa following X-ray therapy |
|
| Sneddon and Wilkinson's subcorneal pustular dermatosis |
|
| Splenic neutropenia |
|
| Status asthmaticus |
|
| Steroid therapy prior to operation for those patients under steroid therapy |
|
| Stevens-Johnson syndrome |
|
| Still's disease in children under the age of sixteen years |
|
| Systemic lupus erythematosus |
|
| Sympathetic ophthalmitis |
|
| Temporal arteritis |
|
| Thrombocytopenic purpura |
|
| Tropical and non-tropical sprue and forms of malabsorption associated with these diseases |
|
| Type II nephritis |
|
| Ulcerative colitis proven by sigmoidoscopy or radiological report |
57 | Dexamethasone Sodium Phosphate | Intra-articular use |
| Injections | Cerebral oedema |
58 | Dexamphetamine Tablets, B.P...... | Any disease or condition in a pensioner |
59 | (1) Dextromoramide Tablets....... | Treatment in neoplastic disease |
| (2) Dextromoramide Injection |
|
60 | Diazepam Injection ............. | Cardioversion |
|
| Endoscopic examination |
|
| Epilepsy |
|
| Minor operative procedure |
|
| Premedication induction of anaesthesia |
|
| Upper motor neurone lesion |
61 | Diazepam Syrup and 10 mg. tablet | Epilepsy |
|
| Upper motor neurone lesion |
62 | Diazepam Tablets 2 mg. and 5 mg. | Epilepsy |
|
| Upper motor neurone lesion |
|
| Treatment in multiple sclerosis |
|
| Stiff-man syndrome |
63 | Dienoestrol Cream ............. | Any disease or condition in a pensioner |
64 | Dienoestrol Tablets, B.P.......... | Carcinoma of the prostate |
|
| Mammary carcinoma |
|
| Any disease or condition in a pensioner |
65 | Dihydrotachysterol............. | Parathyroid deficiency |
66 | Diloxanide Furoate Tablets, B.P..... | Amoebic dysentery |
67 | Dimethicone | Ileostomy or colostomy conditions |
68 | Dimethicone Creams............ | Use with surgical appliances |
69 | Dioctyl Sodium Sulphosuccinate with Danthron | Any disease or condition in a pensioner |
70 | Disodium Stilboestrol Diphosphate | Carcinoma of the prostate |
71 | Ditophal | Any disease or condition in a patient receiving treatment in or at an approved hospital |
72 | Doxycycline Hyclate ............ | A disease or condition specified in this column in relation to Chlortetracycline Capsules, B.P. except herpes zoster ophthalmicus |
73 | (1) Erythromycin............... | Brucellosis |
|
| Intestinal amoebiasis |
| (2) Erythromycin ethyl succinate suspension | Leptospirosis |
|
| Lymphogranuloma venereum |
| (3) Erythromycin ethyl succinate | Mycoplasma pneumoniae (Eaton's Agent) |
| chewable tablet | Psittacosis |
|
| Rickettsial infections |
|
| Staphylococcal septicaemia or staphylococcal pneumonia |
Fifth Schedule—continued
First Column_Column | Third Column | |
Item No. | Pharmaceutical Benefit | Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act |
73 | (1) Erythromycin............... | Any bacterial infections or spirochaetal infection or actinomycosis or trachoma where these cannot be treated safely and effectively by sulphonamides or penicillins |
(2) Erythromycin ethyl succinate suspension | ||
| (3) Erythromycin ethyl succinate chewable tablet—continued |
|
| Pre-operative and post-operative therapy where there are reasonable grounds for believing that infection may occur | |
74 | Ethinyloestradiol Tablets, B.P...... | Any disease or condition in a pensioner |
|
| Hereditary telangiectasis |
|
| Pre-menopausal castration syndrome |
|
| Turner's syndrome |
75 | Ethionamide | Tuberculosis |
76 | Ethisterone Tablets, B.P.......... | Turner's syndrome |
77 | Ethyloestrenol ................ | With the written authority of the Director-General, intermittent use for corticosteroid-induced osteoporosis |
|
| Intermittent use for patients on long term treatment with corticosteroids |
78 | Fludrocortisone Tablets, B.P....... | Addison's disease |
|
| Adrenocortical hypoplasia |
|
| Total adrenalectomy |
79 | Flufenamic Acid............... | Any disease or condition in a patient receiving treatment in or at an approved hospital |
80 | Fluorouracil Sodium ............ | Treatment in neoplastic disease |
81 | Fluoxymesterone Tablets, B.P...... | Castration syndrome (male) |
|
| Mammary carcinoma |
|
| With the written authority of the Director-General, intermittent use for corticosteroid-induced osteoporosis |
82 | (1) Fluphenazine Oenanthate ....... | Any disease or condition in a pensioner |
| (2) Fluphenazine Hydrochloride..... | Any disease or condition in a patient receiving treatment in or at an approved hospital |
|
| The treatment of a mental disorder in a person who has, after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that that person received treatment at the hospital and may require further treatment with either or both of the following pharmaceutical benefits:— |
|
| Fluphenazine Oenanthate |
|
| Fluphenazine Hydrochloride |
|
| With the written authority of the Director-General— |
|
| Late-stage malignancy |
|
| Radiation sickness |
|
| Huntington's chorea |
|
| With the written authority of the Director-General, the treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital |
83 | (1) Folic Acid Injection .......... | Macrocytic anaemia |
| (2) Folic Acid Tablets, B.P........ | Sprue or the sprue-like syndrome |
84 | Folinic Acid .................. | Any disease or condition in a patient receiving treatment in or at an approved hospital |
85 | Framycetin Sulphate Tablets ....... | Bowel sterilization preparatory to major surgery |
86 | Fusidic Acid (Sodium Salt or Diethanolamine Salt) | With the written authority of the Director-General, infections where positive bacteriological evidence confirms that Fusidic Acid (Sodium Salt or Diethanolamine Salt) is the only appropriate antibiotic |
Fifth Schedule—continued
First Column_Column | Third Column | |
Item No. | Pharmaceutical Benefit | Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act |
87 | Galactomin Formula No. 11..... | With the written authority of the Director-General— |
|
| Galactosaemia |
|
| Conditions needing an extreme restriction of lactose in the patient's diet, in children under the age of four years |
88 | Galactomin Formula No. 19 .... | With the written authority of the Director-General— Glucose-galactose malabsorption |
89 | Goat's Milk, dehydrated....... | With the written authority of the Director-General, cow's milk allergy in children under the age of four years |
90 | Goat's Milk, Whole (Sterilized) .. | With the written authority of the Director-General— Cow's milk allergy in children under the age of four years |
91 | Griseofulvin Tablets, B.P...... | With the written authority of the Director-General, for use in severe tinea infections due to Microsporum, Trichophyton or Epidermophyton species which have been proven by laboratory examination |
92 | Guanacline Tablets.......... | Any disease or condition in a patient receiving treatment in or at an approved hospital |
93 | Halibut Liver Oil Capsules..... | Any disease or condition in a pensioner |
94 | Haloperidol ............... | Any disease or condition in a pensioner |
|
| Any disease or condition in a patient receiving treatment in or at an approved hospital |
|
| The treatment of a mental disorder in a person who has, after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that the person received treatment at that hospital and may require further treatment with Haloperidol |
|
| With the written authority of the Director-General— |
|
| Late-stage malignancy |
|
| Radiation sickness |
|
| Huntington's chorea |
|
| The treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital |
93 | (1) Hexachlorophane with Chloroxylenol | Any disease or condition in a patient receiving treatment in or at an approved hospital |
| (2) Hexachlorophane with Entsufon |
|
| (3) Hexachlorophane with Lissapol |
|
| (4) Hexachlorophane in Soap Solution |
|
96 | Hydrocortisone Injection ...... | With the written authority of the Director-General— |
|
| Acquired haemolytic anaemia |
|
| Acute disseminated encephalomyelitis |
|
| Acute exfoliative dermatitis |
|
| Acute exophthalmic ophthalmoplegia |
|
| Acute heart block complicating myocardial infarction |
|
| Acute rheumatic carditis |
|
| Addison's disease or other forms of adrenocortical hypoplasia |
|
| Adrenalectomy, total |
|
| Adrenogenital syndrome |
|
| Agranulocytosis |
|
| Behcet's syndrome |
|
| Benign intracranial hypertension |
|
| Cerebral oedema |
Fifth Schedule—continued
First Column_Column | Third Column | |
Item No. | Pharmaceutical Benefit | Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act |
96 | Hydrocortisone Injection—continued | Cerebral tumors |
| Cranial arteritis | |
|
| Cushing's syndrome including hyperadrenocorticalism |
|
| Dermatomyositis |
|
| Encephalitis |
|
| Encephalomyelitis |
|
| Giant cell thyroiditis proven by biopsy |
|
| Guillain-Barré syndrome |
|
| Hamman-Rich syndrome—diffuse interstitial pulmonary fibrosis |
|
| Hansen's disease |
|
| Hepatitis, progressive or continuing, proven by biopsy or biochemistry |
|
| Hodgkin's disease |
|
| Hypoplastic anaemia |
|
| Idiopathic hypercalcaemia |
|
| Inflammatory conditions of the uveal tract and retina |
|
| Interstitial keratitis due to syphilis or vernal conjunctivitis |
|
| Keratoplasty |
|
| Leucine sensitive hypoglycaemia |
|
| Leukaemia |
|
| Lymphosarcoma and follicular lymphoma |
|
| Malignancy treatment in conjunction with radiotherapy or chemotherapy |
|
| Meningitis |
|
| Metastatic breast cancer |
|
| Mycosis fungoides |
|
| Nephrosis or nephrotic syndrome |
|
| Neuromyelitis optica |
|
| Oedema of the spinal cord following trauma or infections |
|
| Optic neuritis following removal of tumors of the brain |
|
| Panhypopituitarism |
|
| Pemphigus |
|
| Periarteritis |
|
| Progressive transverse myelitis |
|
| Pseudohermaphroditism |
|
| Pulmonary cosinophilia |
|
| Purpura, Henoch's |
|
| Regional ileitis (Crohn's disease) |
|
| Reticulum cell sarcoma |
|
| Sarcoidosis |
|
| Scleroderma |
|
| Severe reactions of the skin and mucosa following X-ray therapy |
|
| Sneddon and Wilkinson's subcorneal pustular dermatosis |
|
| Splenic neutropenia |
|
| Status asthmaticus |
|
| Steroid therapy prior to operation for those patients under steroid therapy |
|
| Stevens-Johnson syndrome |
|
| Still's disease in children under the age of sixteen years |
|
| Systemic lupus erythematosus |
|
| Sympathetic ophthalmitis |
|
| Temporal arteritis |
|
| Thrombocytopenic purpura |
|
| Tropical and non-tropical sprue and forms of malabsorption associated with these diseases |
Fifth Schedule—continued
First Column | Second Column | Third Column |
Item No. | Pharmaceutical Benefit | Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act |
96 | Hydrocortisone Injection—continued | Type II nephritis |
| Ulcerative colitis proven by sigmoidoscopy or radiological report | |
97 | Hydrocortisone Acetate Injection, B.P. | Intra-articular use |
98 | Hydrocortisone Acetate, B.P. with Neomycin Sulphate, B.P. Ear drops and ear ointment | For the treatment of diseases of the ear |
99 | Hydrocortisone Sodium Succinate Injection | Acute adrenal failure due to medical or surgical crisis Prophylaxis of adrenal insufficiency during and after major surgery for patients already on steroid therapy |
|
| Stevens-Johnson syndrome |
100 | Hydrocortisone Ear Drops ..... | For the treatment of diseases of the ear |
101 | Hydroxocobalmin Injection, B.P.. | Established megalocytic anaemia |
|
| Neuroblastoma |
|
| Sub-acute combined degeneration of the cord |
|
| Treatment in post-gastrectomy |
102 | Hydroxyprogesterone ........ | Endometrial carcinoma |
|
| Progresterone deficiency proven by hormonal assay of lateral wall smear |
103 | Idoxuridine ............... | Infections caused by Herpes Simplex Virus |
104 | (1) Imipramine Tablets, B.P..... | Any disease or condition in a pensioner |
| (2) Imipramine Hydrochloride, B.P. | Any disease or condition in a patient receiving treatment in or at an approved hospital |
|
| The treatment of a mental disorder in a person who has, after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that that person received treatment at the hospital and may require further treatment with Imipramine Hydrochloride B.P. or Imipramine Tablets, B.P. |
|
| With the written authority of the Director-General, the treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital |
105 | Indomethacin Capsule ........ | Rheumatoid arthritis or osteoarthritis not responding to salicylates |
|
| Acute attacks of gout |
|
| Ankylosing spondylitis |
|
| Psoriatic arthritis |
|
| Reiter's syndrome |
106 | Indomethacin Suppositories .... | For the treatment of the following conditions in persons who cannot tolerate oral indomethacin— |
|
| Acute attacks of gout |
|
| Ankylosing spondylitis |
|
| Osteoarthritis not responding to salicylates |
|
| Psoriatic arthritis |
|
| Reiter's syndrome |
|
| Rheumatoid arthritis not responding to salicylates |
107 | Isoniazid Tablets, B.P......... | Tuberculosis |
108 | Isoprenaline Hydrochloride Tablets | For long term use in patients suffering from Stokes-Adams' seizures due to heart block |
109 | Kanamycin Sulphate Capsules, Injections and Oral Solution | With the written authority of the Director-General, infections where positive bacteriological evidence confirms that Kanamycin Sulphate is the only appropriate antibiotic |
110 | Kitasamycin .............. | Any disease or condition in a patient receiving treatment in or at an approved hospital |
111 | Levorphanol Tartrate......... | Obstetrical use Severe intractable pain |
Fifth Schedule—continued
First Column_Column | Third Column | |
Item No. | Pharmaceutical Benefit | Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whoso treatment it may be prescribed) for supply under Part VII. of the Act |
112 | Lincomycin Hydrochloride ..... | Gram positive coccal infections |
|
| Osteomyelitis |
113 | Liothyronine Tablets, D.P...... | Myxoedema |
114 | Lipopancreatin............. | Fibrocystic disease |
|
| Pancreatico-duodenectomy |
|
| Pancreatic steatorrhea |
115 | Lofenalac ................ | With the written authority of the Director-General, phenylketonuria |
116 | Medroxyprogesterone Acetate Tablets 2.5 mg. and 10 mg. | Adenocarcinoma of the uterus (endometrial carcinoma) |
117 | Medroxyprogesterone Acetate Tablets 100 mg. | Adenocarcinoma of the body of the uterus Hypernephroma |
|
| |
118 | Medroxyprogesterone Acetate Injections | Adenocarcinoma of the uterus (endometrial carcinoma) Hypernephroma |
|
| Progesterone deficiency proven by hormonal assay of lateral wall smear |
119 | Melphalan ................ | Treatment in neoplastic disease |
120 | Mercaptopurine Tablets, B.P.... | Allergic angiitis |
|
| Treatment in neoplastic disease |
|
| Lupus erythematosus |
|
| Nephrosis or Nephrotic syndrome |
|
| Periarteritis |
121 | Mestanolone .............. | Mammary carcinoma |
|
| With the written authority of the Director-General, intermittent use for corticosteroid-induced osteoporosis |
|
| Intermittent use for patients on long-term treatment with corticosteroids |
123 | Methacycline .............. | A disease or condition specified in this column in relation to Chlortetracycline Capsules, B.P., except herpes zoster ophthalmicus |
123 | (1) Methandienone Tablets, B.P... | With the written authority of the Director-General, intermittent use for corticosteroid-induced osteoporosis |
| (2) Methenolone Acetate....... |
|
|
| Intermittent use for patients on long-term treatment with corticosteroids |
124 | Methicillin Injection, B.P...... | Proven or suspected staphylococcal septicaemia |
125 | Methotrexate Tablets......... | Treatment in neoplastic disease |
126 | Methotrexate Injections....... | Any disease or condition in a patient receiving treatment in or at an approved hospital |
127 | (1) Methylamphetamine Injection, B.P. | Any disease or condition in a pensioner |
| (2) Methylamphetamine Tablets, B.P. |
|
128 | (1) Methylprednisolone Tablets, B.P. | With the written authority of the Director-General— |
| Acquired haemolytic anaemia | |
| (2) Methylprednisolone Capsules | Acute disseminated encephalomyelitis |
|
| Acute exfoliative dermatitis |
|
| Acute exophthalmic ophthalmoplegia |
|
| Acute heart block complicating myocardial infarction |
|
| Acute phase of herpes zoster |
|
| Acute rheumatic carditis |
|
| Adrenogenital syndrome |
|
| Agranulocytosis |
|
| Behcet's syndrome |
|
| Benign intracranial hypertension |
|
| Cerebral oedema |
|
| Cerebral tumors |
|
| Cranial arteritis |
|
| Cushing's syndrome including hyperadrenocorticalism |
|
| Dermatomyositis |
Fifth Schedule—continued
First Column_Column | Third Column | |
Item No. | Pharmaceutical Benefit | Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act |
128 | (1) Methylprednisolone Tablets, B.P. | Encephalitis |
|
| Encephalomyelitis |
| (2) Methylprednisolone Capsules—continued | Giant cell thyroiditis proven by biopsy |
|
| Guillain-Barré syndrome |
|
| Hamman-Rich syndrome—diffuse interstitial pulmonary fibrosis |
|
| Hansen's disease |
|
| Hepatitis, progressive or continuing, proven by biopsy or biochemistry |
|
| Hodgkin's disease |
|
| Hypoplastic anaemia |
|
| Idiopathic hypercalcaemia |
|
| Inflammatory conditions of the uveal tract and retina |
|
| Interstitial keratitis due to syphilis or vernal conjunctivitis |
|
| Keratoplasty |
|
| Leucine sensitive hypoglycaemia |
|
| Leukaemia |
|
| Lymphosarcoma and follicular lymphoma |
|
| Malignancy treatment in conjunction with radiotherapy or chemotherapy |
|
| Malignant exophthalmos |
|
| Meningitis |
|
| Metastatic breast cancer |
|
| Mycosis fungoides |
|
| Nephrosis or nephrotic syndrome |
|
| Neuromyelitis optica |
|
| Nodular nonsuppurative panniculitis (Christian-Weber disease) |
|
| Oedema of the spinal cord following trauma or infections |
|
| Optic neuritis following removal of tumors of the brain |
|
| Panhypopituitarism |
|
| Pemphigus |
|
| Periarteritis |
|
| Progressive transverse myelitis |
|
| Pseudohermaphroditism |
|
| Pulmonary cosinophilia |
|
| Purpura, Henoch's |
|
| Regional ileitis (Crohn's disease) |
|
| Reticulum cell sarcoma |
|
| Sarcoidosis |
|
| Scleroderma |
|
| Severe reactions of the skin and mucosa following X-ray therapy |
|
| Sneddon and Wilkinson's subcorneal pustular dermatosis |
|
| Splenic neutropenia |
|
| Status asthmaticus |
|
| Steroid therapy prior to operation for these patients under steroid therapy |
|
| Stevens-Johnson syndrome |
|
| Still's disease in children under the age of sixteen years |
|
| Systemic lupus erythematosus |
|
| Sympathetic ophthalmitis |
|
| Temporal arteritis |
|
| Thrombocytopenic purpura |
|
| Tropical and non-tropical sprue and forms of malabsorption associated with these diseases |
|
| Type II nephritis |
|
| Ulcerative colitis proved by sigmoidoscopy or radiological report |
Fifth Schedule—continued
First Column_Column | Third Column | |
Item No. | Pharmaceutical Benefit | Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act |
129 | (1) Methyltestosterone Tablets, B.P. | Castration syndrome (male) |
|
| Klinefelter Reifenstein Albright syndrome |
| (2) Methyltestosterone, B.P. .. | Mammary carcinoma |
130 | Metyrapone ............... | Any disease or condition in a patient receiving treatment in or at an approved hospital |
131 | Minafen ................. | With the written authority of the Director-General, phenylketonuria |
132 | Morphine Sulphate, B.P. with Tacrine Tablets | Severe intractable pain |
133 | Mustine Hydrochloride Injection | Treatment in neoplastic disease |
134 | Nalidixic Acid............. | Urinary tract infections in which sulphonamides are not effective |
135 | Nandrolone Phenylpropionate Injection, B.P. | Mammary carcinoma |
| With the written authority of the Director-General, intermittent use for corticosteroid-induced osteoporosis | |
136 | Nandrolone Decanoate ........ | Mammary carcinoma |
|
| With the written authority of the Director-General, intermittent use for corticosteroid-induced osteoporosis |
|
| Intermittent use for patients on long-term treatment with corticosteroids |
137 | Natamycin | Monilia infections |
138 | Neomycin Sulphate Powder .... | With the written authority of the Director-General, intermittent use by inhalation in fibrocystic disease |
139 | Neomycin Sulphate, B.P. with Gramicidin, Thonzonium Bromide, Thonzylamine Hydrochloride and Hydrocortisone Acetate, B.P. | For the treatment of diseases of the car |
140 | Neomycin Tablets, B.P......... | Bowel sterilization preparatory to major surgery |
|
| Portal-systemic encephalopathy |
141 | Neomycin Undecenoate with Bacitracin Zinc | For the treatment of diseases of the ear |
142 | Nicotinic Acid Tablets, B.P..... | Any disease or condition in a pensioner |
143 | Nitrazepam | Myoclonic epilepsy in children |
144 | (1) Nitrofurantoin Tablets, B.P... | Urinary tract infections |
| (2) Nitrofurantoin Oral Suspension |
|
145 | Nitromin ................. | Treatment in neoplastic disease |
146 | (1) Nortriptyline Hydrochloride, B.P. | Any disease or condition in a pensioner |
|
| Any disease or condition in a patient receiving treatment in or at an approved hospital |
| (2) Nortriptyline Tablets, B.P.... |
|
| (3) Nortriptyline Capsules, B.P... | The treatment of a mental disorder in a person who has, after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that that person received treatment at the hospital and may require further treatment with Nortriptyline Hydrochloride, B.P., Nortriptyline Tablets, B.P. or Nortriptyline Capsules, B.P. |
|
| With the written authority of the Director-General, the treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital |
147 | Nutramigen ............... | With the written authority of the Director-General— |
|
| Cow's milk allergy in children under the age of four years |
|
| Galactosaemia |
|
| Lactose intolerance |
|
| Fibrocystic disease of the pancreas |
Fifth Schedule—continued
First Column_Column | Third Column | |
Item No. | Pharmaceutical Benefit | Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act |
148 | Nystatin Tablets, B.P......... | Monilia infections |
149 | Orciprenaline Sulphate Injection.. | Any disease or condition in a patient receiving treatment in or at an approved hospital |
150 | Oxycodone Pectinate......... | Treatment in neoplastic disease |
151 | Oxymesterone.............. | With the written authority of the Director-General, intermittent use for corticosteroid-induced osteoporosis |
|
| Intermittent use for patients on long-term treatment with corticosteroids |
152 | Oxymetholone ............. | With the written authority of the Director-General— |
|
| Aplastic anaemia |
|
| Primary refractory anaemias |
153 | (1) Oxytetracycline Hydrochloride Capsules | A disease or condition specified in this column in relation to Chlortetracycline Capsules, B.P., except herpes zoster ophthalmicus |
| (2) Oxytetracycline Tablets, B.P.. |
|
| (3) Oxytetracycline Injections... |
|
| (4) Calcium di-Oxytetracycline Oral Suspension |
|
| (5) Calcium di-Oxytetracycline Paediatric Drops |
|
154 | Oxytetracycline Hydrochloride with a buffering agent and Nystatin | Broad spectrum antibiotic therapy of premature infants, of patients under steroid therapy or of cases complicated by intestinal moniliasis |
|
| A second or repeated course of broad spectrum antibiotic therapy for a disease or condition specified in this column in relation to Chlortetracycline Capsules, B.P., except herpes zoster ophthalmicus |
155 | (1) Pancreatin, B.P........... | Fibrocystic disease |
| (2) Pancreatin Enzyme U.S.N.F. XII | Pancreatico-duodenectomy |
|
| Pancreatic steatorrhea |
156 | Para-Aminosalicyclic Acid..... | Tuberculosis |
157 | (1) Paracetamol Suspension..... | Any disease or condition in a pensioner |
| (2) Paracetamol Tablets, B.P. |
|
158 | Paracetamol with Codeine Phosphate and Pentobartitone Sodium | Any disease or condition in a pensioner |
159 | Paramethasone Acetate ....... | With the written authority of the Director-General— |
|
| Acquired haemolytic anaemia |
|
| Acute disseminated encephalomyelitis |
|
| Acute exfoliative dermatitis |
|
| Acute exophthalmic ophthalmoplegia |
|
| Acute heart block complicating myocardial infarction |
|
| Acute phase of herpes zoster |
|
| Acute rheumatic carditis |
|
| Addison's disease or other forms of adrenocortical hypoplasia |
|
| Adrenalectomy, total |
|
| Adrenogenital syndrome |
|
| Agranulocytosis |
|
| Behcet's syndrome |
|
| Benign intracranial hypertension |
|
| Cerebral oedema |
|
| Cerebral tumors |
|
| Cranial arteritis |
|
| Cushing's syndrome including hyperadrenocorticalism |
|
| Dermatomyositis |
|
| Encephalitis |
|
| Encephalomyelitis |
|
| Giant cell thyroiditis proven by biopsy |
|
| Guillain-Barré syndrome |
|
| Hamman-Rich syndrome—diffuse interstitial pulmonary fibrosis |
Fifth Schedule—continued
First Column_Column | Third Column | |
Item No. | Pharmaceutical Benefit | Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act |
159 | Paramethasone Acetate—continued | Hansen's disease |
|
| Hepatitis, progressive or continuing, proven by biopsy or biochemistry |
|
| Hodgkin's disease |
|
| Hypoplastic anaemia |
|
| Idiopathic hypercalcaemia |
|
| Inflammatory conditions of the uveal tract and retina |
|
| Interstitial keratitis due to syphilis or vernal conjunctivitis |
|
| Keratoplasty |
|
| Leucine sensitive hypoglycaemia |
|
| Leukaemia |
|
| Lymphosarcoma and follicular lymphoma |
|
| Malignancy treatment in conjunction with radiotherapy or chemotherapy |
|
| Meningitis |
|
| Metastatic breast cancer |
|
| Mycosis fungoides |
|
| Nephrosis or nephrotic syndrome |
|
| Neuromyelitis optica |
|
| Oedema of the spinal cord following trauma or infections |
|
| Optic neuritis following removal of tumors of the brain |
|
| Panhypopituitarism |
|
| Pemphigus |
|
| Periarteritis |
|
| Progressive transverse myelitis |
|
| Pseudohermaphroditism |
|
| Pulmonary eosinophilia |
|
| Purpura, Henoch's |
|
| Regional ileitis (Crohn's disease) |
|
| Reticulum cell sarcoma |
|
| Sarcoidosis |
|
| Scleroderma |
|
| Severe reactions of the skin and mucosa following X-ray therapy |
|
| Sneddon and Wilkinson's subcorneal pustular dermatosis |
|
| Splenic neutropenia |
|
| Status asthmaticus |
|
| Steroid therapy prior to operation for those patients under steroid therapy |
|
| Stevens-Johnson syndrome |
|
| Still's disease in children under the age of sixteen years |
|
| Systemic lupus erythematosus |
|
| Sympathetic ophthalmitis |
|
| Temporal arteritis |
|
| Thrombocytopenic purpura |
|
| Tropical and non-tropical sprue and forms of malabsorption associated with these diseases |
|
| Type II nephritis |
|
| Ulcerative colitis proven by sigmoidoscopy or radiological report |
160 | (1) Paraffin Liquid Emulsion.... | Any disease or condition in a pensioner |
| (2) Paraffin Liquid Emulsion with Phenolphthalein |
|
161 | Pargyline Hydrochloride....... | Any disease or condition in a patient receiving treatment in or at an approved hospital |
Fifth Schedule—continued
First Column_Column | Third Column | |
Item No. | Pharmaceutical Benefit | Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions us to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act |
162 | Penicillamine.............. | With the written authority of the Director-General— |
|
| Cystinosis |
|
| Cystinuria with calculus formation |
|
| Treatment of cold agglutinin haemoglobinuria |
|
| Acute heavy metal intoxication |
|
| Wilson's disease (hepatolenticular degeneration) |
163 | (1) Penicillin Benzathine Tablets and Capsules | Prevention of recurrent streptococcal infections, including rheumatic fever |
| (2) Penicillin Benzyl Tablets, B.P. |
|
| (3) Penicillin Benzyl Capsules |
|
164 | Pethidine Hydrochloride with Levallorphan Tartrate | Obstetrical use |
165 | (1) Phenylbutazone Tablets, B.P.. | Rheumatoid arthritis or osteoarthritis not responding to salicylates |
| (2) Phenylbutazone Capsules ... |
|
|
| Acute attacks of gout |
|
| Ankylosing spondylitis |
|
| Psoriatic arthritis |
|
| Reiter's syndrome |
166 | (1) Phenylbutazone Suppositories. | For the treatment of the following conditions in persons who cannot tolerate Phenylbutazone Tablets, B.P. and Phenylbutazone Capsules:— |
| (2) Phenylbutazone Injection.... | |
|
| Acute attacks of gout |
|
| Ankylosing spondylitis |
|
| Psoriatic arthritis |
|
| Reiter's syndrome |
|
| Rheumatoid arthritis or osteoarthritis not responding to salicylates |
167 | Phytomenadione Injection, B.P... | Antidote to anticoagulants |
168 | Pituitary, Posterior Lobe, Insufflation | Diabetes insipidus |
169 | Polymyxin B. Sulphate Powder.. | With the written authority of the Director-General— Intermittent use by inhalation in fibrocystic disease |
170 | Polymyxin B. Sulphate Neomycin Sulphate and Hydrocortisone | For the treatment of diseases of the ear |
171 | Polyoestradiol Phosphate...... | Carcinoma of the prostate |
172 | Prednisolone Sodium Phosphate Retention Enema and Suppository | With the written authority of the Director-General— Ulcerative colitis proven by sigmoidoscopy or radiological report |
|
| Proctitis proven by sigmoidoscopy |
173 | Prednisolone Tablets, B.P...... | With the written authority of the Director-General— |
|
| Acquired haemolytic anaemia |
|
| Acute disseminated encephalomyelitis |
|
| Acute exfoliative dermatitis |
|
| Acute exophthalmic ophthalmoplegia |
|
| Acute heart block complicating myocardial infarction |
|
| Acute phase of herpes zoster |
|
| Acute rheumatic carditis |
|
| Adrenogenital syndrome |
|
| Agranulocytosis |
|
| Behcet's syndrome |
|
| Benign intracranial hypertension |
|
| Cerebral oedema |
|
| Cerebral tumors |
|
| Cranial arteritis |
|
| Cushing's syndrome including hyperadrenocorticalism |
|
| Dermatomyositis |
|
| Encephalitis |
|
| Encephalomyelitis |
|
| Giant cell thyroiditis proven by biopsy |
|
| Guillain-Barré syndrome |
Fifth Schedule—continued
First Column_Column | Third Column | |
Item No. | Pharmaceutical Benefit | Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act |
173 | Prednisolone Tablets, B.P.—continued | Hamman-Rich syndrome—diffuse interstitial pulmonary fibrosis |
|
| Hansen's disease |
|
| Hepatitis, progressive or continuing proven by biopsy or biochemistry |
|
| Hodgkin's disease |
|
| Hypoplastic anaemia |
|
| Idiopathic hypercalcaemia |
|
| Inflammatory conditions of the uveal tract and retina |
|
| Interstitial keratitis due to syphilis or vernal conjunctivitis |
|
| Keratoplasty |
|
| Leucine sensitive hypoglycaemia |
|
| Leukaemia |
|
| Lymphosarcoma and follicular lymphoma |
|
| Malignancy treatment in conjunction with radiotherapy or chemotherapy |
|
| Malignant exophthalmos |
|
| Meningitis |
|
| Metastatic breast cancer |
|
| Mycosis fungoides |
|
| Nephrosis or nephrotic syndrome |
|
| Neuromyelitis optica |
|
| Nodular nonsuppurative panniculitis (Christian-Weber disease) |
|
| Oedema of the spinal cord following trauma or infections |
|
| Optic neuritis following removal of tumors of the brain |
|
| Panhypopituitarism |
|
| Pemphigus |
|
| Periarteritis |
|
| Progressive transverse myelitis |
|
| Pseudohermaphroditism |
|
| Pulmonary cosinophilia |
|
| Purpura, Henoch's |
|
| Regional ileitis (Crohn's disease) |
|
| Reticulum cell sarcoma |
|
| Sarcoidosis |
|
| Scleroderma |
|
| Severe reactions of the skin and mucosa following X-ray therapy |
|
| Sneddon and Wilkinson's subcorneal pustular dermatosis |
|
| Splenic neutropenia |
|
| Status asthmaticus |
|
| Steroid therapy prior to operation for those patients under steroid therapy |
|
| Stevens-Johnson syndrome |
|
| Still's disease in children under the age of sixteen years |
|
| Systemic lupus erythematosus |
|
| Sympathetic ophthalmitis |
|
| Temporal arteritis |
|
| Thrombocytopenic purpura |
|
| Tropical and non-tropical sprue and forms of malabsorption associated with these diseases |
|
| Typo II nephritis |
|
| Ulcerative colitis proven by sigmoidoscopy or radiological report |
174 | Prednisolone Methyl Acetate Injection | Intra-articular use |
Fifth Schedule—continued
First Column_Column | Third Column | |
Item No. | Pharmaceutical Benefit | Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act |
175 | (1) Prednisolone Acetate Injection | Intra-articular use |
| (2) Prednisolone Tertiary Butyl Acetate Injection |
|
176 | Prednisolone Sodium Phosphate and Neomycin Sulphate | For the treatment of diseases of the car |
177 | Prednisolone Sodium Succinate.. | Acute adrenal failure due to medical or surgical crisis |
|
| Prophylaxis of adrenal insufficiency during and after major surgery for patients already on steroid therapy |
|
| Stevens-Johnson syndrome |
178 | Prednisone Tablets, B.P....... | With the written authority of the Director-General— |
|
| Acquired haemolytic anaemia |
|
| Acute disseminated encephalomyelitis |
|
| Acute exfoliative dermatitis |
|
| Acute exophthalmic ophthalmoplegia |
|
| Acute heart block complicating myocardial infarction |
|
| Acute phase of herpes zoster |
|
| Acute rheumatic carditis |
|
| Adrenogenital syndrome |
|
| Agranulocytosis |
|
| Behcet's syndrome |
|
| Benign intracranial hypertension |
|
| Cerebral oedema |
|
| Cerebral tumors |
|
| Cranial arteritis |
|
| Cushing's syndrome including hyperadrenocorticalism |
|
| Dermatomyositis |
|
| Encephalitis |
|
| Encephalomyelitis |
|
| Giant cell thyroiditis proven by biopsy |
|
| Guillain-Barré syndrome |
|
| Hamman-Rich syndrome—diffuse interstitial pulmonary fibrosis |
|
| Hansen's disease |
|
| Hepatitis, progressive or continuing, proven by biopsy or biochemistry |
|
| Hodgkin's disease |
|
| Hypoplastic anaemia |
|
| Idiopathic hypercalcaemia |
|
| Inflammatory conditions of the uveal tract and retina |
|
| Interstitial keratitis due to syphilis or vernal conjunctivitis |
|
| Keratoplasty |
|
| Leucine sensitive hypoglycaemia |
|
| Leukaemia |
|
| Lymphosarcoma and follicular lymphoma |
|
| Malignancy treatment in conjunction with radiotherapy or chemotherapy |
|
| Malignant exophthalmos |
|
| Meningitis |
|
| Metastatic breast cancer |
|
| Mycosis fungoides |
|
| Nephrosis or nephrotic syndrome |
|
| Neuromyelitis optica |
|
| Nodular nonsuppurative panniculitis (Christian-Weber disease) |
|
| Oedema of the spinal cord following trauma or infections |
|
| Optic neuritis following removal of tumors of the brain |
Fifth Schedule—continued
First Column_Column | Third Column | |
Item No. | Pharmaceutical Benefit | Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act |
178 | Prednisone Tablets—continued | Panhypopituitarism |
|
| Pemphigus |
|
| Periarteritis |
|
| Progressive transverse myelitis |
|
| Pseudohermaphroditism |
|
| Pulmonary eosinophilia |
|
| Purpura, Henoch's |
|
| Regional ileitis (Crohn's disease) |
|
| Reticulum cell sarcoma |
|
| Sarcoidosis |
|
| Scleroderma |
|
| Severe reactions of the skin and mucosa following X-ray therapy |
|
| Sneddon and Wilkinson's subcorneal pustular dermatosis |
|
| Splenic neutropenia |
|
| Status asthmaticus |
|
| Steroid therapy prior to operation for those patients under steroid therapy |
|
| Stevens-Johnson syndrome |
|
| Still's disease in children under the age of sixteen years |
|
| Systemic lupus erythematosus |
|
| Sympathetic ophthalmitis |
|
| Temporal arteritis |
|
| Thrombocytopenic purpura |
|
| Tropical and non-tropical sprue and forms of malabsorption associated with these diseases |
|
| Type II nephritis |
|
| Ulcerative colitis proven by sigmoidoscopy or radiological report |
179 | Procarbazine Hydrochloride.... | Treatment in neoplastic disease |
180 | Progesterone | Progesterone deficiency proven by hormonal assay of lateral wall smear |
181 | Propranolol Hydrochloride..... | Any disease or condition in a patient receiving treatment in or at an approved hospital |
182 | Prosobee ................. | With the written authority of the Director-General— |
|
| Galactosaemia |
|
| Homocystinuria |
|
| Lactose intolerance |
|
| Milk allergy in children under the age of four years |
183 | Protriptyline Hydrochloride .... | Any disease or condition in a pensioner |
|
| Any disease or condition in a patient receiving treatment in or at an approved hospital |
|
| The treatment of a mental disorder in a person who has, after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that that person received treatment at the hospital and may require further treatment with Protriptyline Hydrochloride |
|
| With the written authority of the Director-General— |
|
| The treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital |
184 | Pyrazinamide.............. | Any disease or condition in a patient receiving treatment in or at an approved hospital |
185 | (1) Pyridostigmine Injection, B.P. | Myasthenia gravis |
| (2) Pyridostigmine Tablets, B.P. |
|
186 | Pyridoxine Hydrochloride Tablets | Peripheral neuritis due to isoniazid therapy |
|
| Radiation sickness |
187 | Pyrimethamine Tablets........ | Treatment of toxoplasmosis |
Fifth Schedule—continued
First Column_Column | Third Column | |
Item No. | Pharmaceutical Benefit | Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act |
188 | (1) Quinine Bisulphate Tablets, B.P. | Dystrophia myotonica |
|
| Malaria |
| (2) Quinine Dihydrochloride Tablets | Myotonia atrophica |
|
| Myotonia congenita |
| (3) Quinine Hydrochloride Tablets | Any disease or condition in a pensioner |
| (4) Quinine Sulphate Tablets, B.P. |
|
189 | (1) Riboflavine Tablets........ | Any disease or condition in a pensioner |
| (2) Senna Fruit Extract (standardized) |
|
190 | (1) Sodium Aminosalicylate Tablets, B.P. | Tuberculosis |
| (2) Sodium Aminosalicylate Injection |
|
| (3) Sodium Aminosalicylate Cachets |
|
| (4) Sodium Aminosalicylate Granules |
|
| (5) Sodium Aminosalicylate with Isoniazid, B.P. |
|
191 | Sodium Folate............. | Macrocytic anaemia |
|
| Sprue or the sprue-like syndrome |
192 | Spiramycin................ | Serologically proven active toxoplasmosis |
|
| Staphylococcal septicaemia or staphylococcal pneumonia |
|
| Any gram positive bacterial infections where these cannot be treated safely and effectively by sulphonamides or penicillins |
193 | Spironolactone Tablets, B.P..... | With the written authority of the Director-General, to supplement other diuretics when these have proved inadequate |
|
| Myasthenia Gravis |
194 | Stanolone ................ | Mammary carcinoma |
|
| With the written authority of the Director-General, intermittent use for corticosteroid-induced osteoporosis |
|
| Intermittent use for patients on long-term treatment with corticosteroids |
195 | Stanozolol ................ | With the written authority of the Director-General, intermittent use for corticosteroid-induced osteoporosis |
|
| Intermittent use for patients on long-term treatment with corticosteroids |
196 | (1) Stilboestrol Injection....... | Carcinoma of the prostate |
| (2) Stilboestrol Tablets, B.P..... | Mammary carcinoma |
|
| Any disease or condition in a pensioner |
|
| Hereditary Telangiectasis |
197 | Streptomycin Sulphate Injections | Bacillary dysentery that is resistant to the sulphonamides |
|
| Brucellosis |
|
| Chancroid |
|
| Endocarditis due to Streptococcus faecalis or Streptococcus viridans |
|
| Friedlander bacillus infections |
|
| Haemophilus influenzae infections |
|
| Plague |
|
| Pseudomonas pyocyanea infections |
|
| Rat-bite fever (Streptobacillus moniliformis) |
|
| Salmonella infections |
|
| Surgical conditions of the bowel (pre-operative and post-operative) |
|
| Surgical conditions of the thoracic organs |
|
| Tuberculosis |
|
| Tularaemia |
|
| Urinary tract infections that are resistant to the sulphonamides |
Fifth Schedule—continued
First Column_Column | Third Column | |
Item No. | Pharmaceutical Benefit | Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act |
198 | Sulphasalazine............. | Ulcerative colitis |
199 | Sulphomyxin Sodium ........ | Any disease or condition in a patient receiving treatment in or at an approved hospital |
200 | Sulthiame ................ | For use where other anticonvulsants have failed |
201 | (1) Surgical Cement ......... | Ileostomy or colostomy conditions |
| (2) Surgical Cement Solvent.... | For use with surgical appliances |
202 | (1) Sustanon .............. | Castration syndrome (male) |
| (2) Testosterone Implants, B.P... | Klinefelter Reifenstein Albright syndrome |
| (3) Testosterone Oenanthate.... | Mammary carcinoma |
| (4) Testosterone Propionate Injection, B.P. |
|
203 | Tetanus Antitoxin, B.P. (Bovine) | Patients who have previously received an injection of equine serum |
204 | Tetanus Immune Globulin (Human) | With the written authority of the Director-General, where patients are known to be sensitive to equine serum and bovine serum |
205 | Tetracosactide.............. | Any disease or condition in a patient receiving treatment in or at an approved hospital |
206 | (1) Tetracycline Capsules, B.P... | A disease or condition specified in this column in relation to Chlortetracycline Capsules, B.P., except herpes zoster ophthalmicus |
| (2) Tetracycline Tablets, B.P.... |
|
| (3) Tetracycline Injections...... |
|
| (4) Rolitetracycline.......... |
|
| (5) Tetracycline Hydrochloride Granules, Paediatric Drops and Syrup |
|
| (6) Tetracycline with a buffering agent |
|
207 | (1) Tetracycline with a buffering agent and Amphotericin B | A disease or condition specified in this column in relation to Oxytetracycline Hydrochloride with a buffering agent and Nystatin |
| (2) Tetracycline with a buffering agent and Nystatin |
|
208 | (1) Thiambutosine Tablets, B.P.. | Hansen's disease |
| (2) Thiambutosine Injection..... |
|
209 | Thiethylperazine Tablets and Suppositories | Radiation sickness |
|
| Nausea resulting from cytotoxic therapy |
210 | (1) Thioridazine Tablets, B.P.... | Any disease or condition in a pensioner |
| (2) Thioridazine............ | Any disease or condition in a patient receiving treatment in or at an approved hospital |
|
| The treatment of a mental disorder in a person who has, after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that that person received treatment at the hospital and may require further treatment with either or both of the following pharmaceutical benefits:— |
|
| Thioridazine |
|
| Thioridazine Tablets, B.P. |
|
| With the written authority of the Director-General— |
|
| Late-stage malignancy |
|
| Radiation sickness |
|
| With the written authority of the Director-General, the treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital |
211 | Thyrotrophin.............. | Any disease or condition in a patient receiving treatment in or at an approved hospital |
212 | Tragacanth, Indian (Gum Karaya). | Ileostomy or colostomy conditions |
213 | Trasylol ................. | Any disease or condition in a patient receiving treatment in or at an approved hospital |
214 | Tretamine ................ | Treatment in neoplastic disease |
Fifth Schedule—continued
First Column_Column | Third Column | |
Item No. | Pharmaceutical Benefit | Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act |
215 | Triacetylolcandomycin........ | Brucellosis |
|
| Intestinal amoebiasis |
|
| Leptospirosis |
|
| Lymphogranuloma venereum |
|
| Mycoplasma pneumoniae (Eaton's Agent) |
|
| Psittacosis |
|
| Rickettsial infections |
|
| Staphylococcal septicaemia or staphylococcal pneumonia |
|
| Any bacterial infections or spirochaetal infection or actinomycosis or trachoma where these cannot be treated safely and effectively by sulphonamides or penicillins |
|
| Pre-operative and post-operative therapy where there are reasonable grounds for believing that infection may occur |
216 | (1) Trifluoperazine Tablets, B.P.. | Any disease or condition in a pensioner |
| (2) Trifluoperazine Hydrochloride, B.P. | Any disease or condition in a patient receiving treatment in or at an approved hospital |
|
| The treatment of a mental disorder in a person who has, after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that that person received treatment at the hospital and may require further treatment with Trifluoperazine Hydrochloride, B.P. or Trifluoperazine Tablets B.P. |
|
| With the written authority of the Director-General— Late-stage malignancy Radiation sickness |
|
| With the written authority of the Director-General, the treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital |
217 | Triglyde ................. | With the written authority of the Director-General— Proven malabsorption |
218 | Trimetaphan Injection, B.P..... | Hypotensive for anaesthesia |
219 | Vadrine ................. | Any disease or condition in a patient receiving treatment in or at an approved hospital |
220 | Vasopressin Nasal Spray ...... | Diabetes insipidus |
221 | Velactin ................. | With the written authority of the Director-General— |
|
| Galactosaemia |
|
| Homocystinuria |
|
| Lactose intolerance |
|
| Milk allergy in children under the age of four years |
222 | (1) Vinblastine Sulphate....... | Treatment in neoplastic disease |
| (2) Vincristine Sulphate....... |
|
223 | (1) Viomycin Sulphate........ | Tuberculosis |
| (2)Viomycin Sulphate Injection, B.P. |
|
224 | Vitamin A with Aneurine Hydrochloride, Riboflavine, Nicotinamide, Ascorbic Acid and Vitamin D | Any disease or condition in a pensioner |
THE SCHEDULES
FIRST SCHEDULE Regulation 3.
Amendments of the Second Schedule to the National Health (Pharmaceutical Benefits) Regulations
1. After item 10 insert:—
" 10a | Bacitracin Zinc................ | Bacitracin Zinc with Neomycin Undecenoate ". |
2. After item 15 insert:—
" 15a | Buclosamide.................. | Buclosamide with Salicylic Acid |
|
| Buclosamide with Salicylic Acid and Hydrocortisone Acetate B.P.". |
3. After item 31 insert:—
" 31a | Danthron .................... | Danthron with Dioctyl Sodium Sulphosuccinate ". |
4. After item 41 insert:—
"41a | Dioctyl Sodium Sulphosuccinate .... | Dioctyl Sodium Sulphosuccinate with Danthron ". |
3. Omit item 61, insert:—
" 61 | Glyceryl Guaiacolate ............ | Theophylline with Glyceryl Guaiacolate ". |
6. Omit item 64, insert:—
" 64 | Hydrocortisone, B.P............. | Hydrocortisone B.P. with Polymyxin B. |
|
| Sulphate B.P. and Neomycin Sulphate B.P.". |
7. Insert in item 65, after " Hydrocortisone Acetate B.P. with Chloramphenicol B.P." (in the third column), " Hydrocortisone Acetate B.P. with Oxytetracycline Hydrochloride B.P.".
8. Insert in item 83, after " Polymyxin B. Sulphate B.P. with Neomycin Sulphate B.P. and Gramicidin " (in the third column)—
" Polymyxin B. Sulphate B.P. with Hydrocortisone B.P. and Neomycin Sulphate B.P.
Neomycin Sulphate B.P. with Prednisolone Sodium Phosphate B.P.".
9. After item 83, insert:—
" 83a | Neomycin Undecenoate .......... | Neomycin Undecenoate with Bacitracin Zinc ". |
10. Insert in item 90, after " Oxytetracycline Hydrochloride with a buffering agent and Nystatin B.P." (in the third column), " Oxytetracycline Hydrochloride B.P. with Hydrocortisone Acetate B.P.".
11. Omit from item 92 " XI " (in the second column), insert " XII ".
12. Insert in item 109, after " Polymyxin B. Sulphate B.P. with Propylene Glycol and Acetic Acid " (in the third column), " Polymyxin B. Sulphate B.P. with Neomycin Sulphate B.P. and Hydrocortisone B.P.".
13. Omit item 113, insert:—
" 113 | Prednisolone Sodium Phosphate, B.P.. | Neomycin Sulphate B.P. with Prednisolone Sodium Phosphate B.P.". |
14. Omit item 138, insert:—
" 138 | Tetracycline .................. | Tetracycline with a buffering agent |
|
| Tetracycline with a buffering agent and Amphotericin B. |
|
| Tetracycline with a buffering agent and Nystatin B.P.". |
SECOND SCHEDULE Regulation 4.
Amendments of the Third Schedule to the National Health (Pharmaceutical Benefits) Regulations
1. Omit from item 17 " Polphydroxy ", insert " Polyhydroxy ".
2. After item 34 insert:—
" 34a. Bacitracin Zinc ".
3. After item 55 insert:—
" 55a. Buclosamide ".
4. After item 92 insert:—
" 92a. Clorexolone ".
5. After item 104 insert:—
" 104a. Danthron ".
6. After item 121 insert:—
" 121a. Dioctyl Sodium Sulphosuccinate ".
7. Omit from item 141 " Discoumarin ", insert " Dicoumarin ".
8. After item 167 insert:—
" 167a. Goat's Milk, Whole (Sterilized) ".
9. Omit item 170.
10. Omit from item 203 " Ehereal ", insert " Ethereal ".
11. After item 210 insert:—
" 210a. Meclastine Hydrogen Fumarate ".
12. After item 238 insert:—
" 238a. Neomycin Undecenoate ".
13. Omit from item 254 " Oxyme ", insert " Oxymel ".
14. Omit from item 287 " Physotiomine ", insert " Physostigmine ".
15. After item 331 insert:—
" 331a. Sorbide Nitrate ".
" 331b. Sorbitol ".
16. Omit from item 353 " Sultiame ", insert " Sulthiame ".
17. After item 385 insert:—
" 383a. Typhoid Vaccine ".
.Printed for the Government of the Commonwealth by W. G. Murray at the Government Printing Office, Canberra